FDA Approves First Treatment for MCT8 Deficiency
Published . Updated .
The U.S. Food and Drug Administration today approved Emcitate (tiratricol) tablets for oral suspension to treat peripheral thyrotoxicosis (excess thyroid hormone levels in the blood that causes symptoms, such as rapid heart rate, increased blood pressure and adverse effects on metabolism) in patient
Directly affected
- No company is named in this report.
Indirectly affected
- ACHC ACADIA HEALTHCARE COMPANY INC
GA selected ACHC as a RELATED security because its canonical security name directly matches this event's themes: healthcare. This is an explainable DERIVED market relationship, not a claim that the security was named in the source article.
- ASND ASCENDIS PHARMA A/S
GA selected ASND as a RELATED security because its canonical security name directly matches this event's themes: pharma. This is an explainable DERIVED market relationship, not a claim that the security was named in the source article.
- ATYR ATYR PHARMA INC COM NEW
GA selected ATYR as a RELATED security because its canonical security name directly matches this event's themes: pharma. This is an explainable DERIVED market relationship, not a claim that the security was named in the source article.
- BBIO BRIDGEBIO PHARMA INC
GA selected BBIO as a RELATED security because its canonical security name directly matches this event's themes: pharma. This is an explainable DERIVED market relationship, not a claim that the security was named in the source article.
- DVA DaVita HealthCare Partners, Inc.
GA selected DVA as a RELATED security because its canonical security name directly matches this event's themes: healthcare. This is an explainable DERIVED market relationship, not a claim that the security was named in the source article.
- GEHC GE HEALTHCARE TECHNOLOGIES I
GA selected GEHC as a RELATED security because its canonical security name directly matches this event's themes: healthcare. This is an explainable DERIVED market relationship, not a claim that the security was named in the source article.
Price reaction, T-5 to T+3
The U.S. Food and Drug Administration today approved Emcitate (tiratricol) tablets for oral suspension to treat peripheral thyrotoxicosis (excess thyroid hormone levels in the blood that causes symptoms, such as rapid heart rate, increased…
Source: FDA
Acadia Healthcare (ACHC) since “FDA Approves First Treatment for MCT8 Deficiency,” compared with the market
Since the first closing price after “FDA Approves First Treatment for MCT8 Deficiency,” Acadia Healthcare (ACHC) is +7.70%. The S&P 500 fund (SPY) is +0.29% over the same days, a +7.41% difference versus the market.
Disclosure records for Acadia Healthcare (ACHC) within two months of 28 Sep 2026
- Gilbert Cisneros sell BridgeBio Pharma (BBIO) ($1,001 - $15,000). That is 1 days after publication, inside 30 days. The filing is listed beside the story “FDA Approves First Treatment for MCT8 Deficiency.”
- Rohit Khanna buy GE HealthCare Technologies (GEHC) ($1,001 - $15,000). That is 17 days before publication, inside 30 days. The filing is listed beside the story “FDA Approves First Treatment for MCT8 Deficiency.”
- Rohit Khanna buy GE HealthCare Technologies (GEHC) ($1,001 - $15,000). That is 56 days before publication, inside 60 days. The filing is listed beside the story “FDA Approves First Treatment for MCT8 Deficiency.”
- Rohit Khanna buy GE HealthCare Technologies (GEHC) ($1,001 - $15,000). That is 60 days before publication, inside 60 days. The filing is listed beside the story “FDA Approves First Treatment for MCT8 Deficiency.”
- Rohit Khanna buy GE HealthCare Technologies (GEHC) ($1,001 - $15,000). That is 60 days before publication, inside 60 days. The filing is listed beside the story “FDA Approves First Treatment for MCT8 Deficiency.”
Public disclosure filings, not a recommendation. The filing link is the source document. News use of these reports still sits under 5 U.S.C. § 13107(c).
Who gains and who loses around Acadia Healthcare (ACHC)
Companies tied to this story
- ACHC Acadia Healthcare
For “FDA Approves First Treatment for MCT8 Deficiency,” Acadia Healthcare (ACHC) is linked, with no stored direction, medium confidence. Reason on file: GA selected ACHC as a RELATED security because its canonical security name directly matches this event's themes: healthcare. This is an explainable DERIVED market relationship, not a claim that the security was named in the source article
- ASND Ascendis Pharma A/S
For “FDA Approves First Treatment for MCT8 Deficiency,” Ascendis Pharma A/S (ASND) is linked, with no stored direction, medium confidence. Reason on file: GA selected ASND as a RELATED security because its canonical security name directly matches this event's themes: pharma. This is an explainable DERIVED market relationship, not a claim that the security was named in the source article
- ATYR aTYR PHARMA
aTYR PHARMA (ATYR) is linked, with no stored direction, medium confidence in the 28 Sep 2026 story “FDA Approves First Treatment for MCT8 Deficiency.” Reason on file: GA selected ATYR as a RELATED security because its canonical security name directly matches this event's themes: pharma. This is an explainable DERIVED market relationship, not a claim that the security was named in the source article
- BBIO BridgeBio Pharma
For “FDA Approves First Treatment for MCT8 Deficiency,” BridgeBio Pharma (BBIO) is linked, with no stored direction, medium confidence. Reason on file: GA selected BBIO as a RELATED security because its canonical security name directly matches this event's themes: pharma. This is an explainable DERIVED market relationship, not a claim that the security was named in the source article
- DVA Davita
Davita (DVA) is linked, with no stored direction, medium confidence in the 28 Sep 2026 story “FDA Approves First Treatment for MCT8 Deficiency.” Reason on file: GA selected DVA as a RELATED security because its canonical security name directly matches this event's themes: healthcare. This is an explainable DERIVED market relationship, not a claim that the security was named in the source article
- GEHC GE HealthCare Technologies
In “FDA Approves First Treatment for MCT8 Deficiency,” GE HealthCare Technologies (GEHC) is linked, with no stored direction, medium confidence. Reason on file: GA selected GEHC as a RELATED security because its canonical security name directly matches this event's themes: healthcare. This is an explainable DERIVED market relationship, not a claim that the security was named in the source article
How “FDA Approves First Treatment for MCT8 Deficiency” reaches Acadia Healthcare (ACHC)
The 28 Sep 2026 story “FDA Approves First Treatment for MCT8 Deficiency” names Acadia Healthcare (ACHC) because of this story.
For Acadia Healthcare (ACHC), the reason on file says GA selected ACHC as a RELATED security because its canonical security name directly matches this event's themes: healthcare. This is an explainable DERIVED market relationship, not a claim that the security was named in the source article
Also listed, Ascendis Pharma A/S (ASND): GA selected ASND as a RELATED security because its canonical security name directly matches this event's themes: pharma. This is an explainable DERIVED market relationship, not a claim that the security was named in the source article
Dates and price levels for Acadia Healthcare (ACHC)
ACHC traded between 26.75 and 32.03 across 20 sessions. The latest close on file is 30.20. ASND traded between 219.69 and 240.84 across 20 sessions. The latest close on file is 229.99. ATYR traded between 0.17 and 0.41 across 20 sessions. The latest close on file is 0.17.
A simple score for Acadia Healthcare (ACHC)
46 out of 100
“FDA Approves First Treatment for MCT8 Deficiency” scores 46 out of 100. The score uses 1 sources, and 6 linked companies.